The Readout LOUD-logo

The Readout LOUD

News & Politics Podcasts >

More Information

Location:

United States

Twitter:

@statnews

Language:

English


Episodes

Episode 29: A Hong Kong heat-check, a $20 million wrist slap, and pharma's (other) diversity problem

9/20/2018
More
Is a biotech bubble inflating in China? Do the feds coddle CEOs? And why don't clinical trials look like America?

Duration:00:24:38

Episode 28: Founders' funds, doctors' disclosures, and the subtle art of beeping

9/13/2018
More
Is biotech too founder-friendly? Is honesty overrated? And how do you tell a good beep from a bad one?

Duration:00:22:57

Episode 27: Live from Boston!

9/6/2018
More
Should genome editors be worried? Has 2018 been a bummer? And are voters ready to love Big Pharma? We discuss this and more on a special live episode from the BioPharm America conference in Boston.

Duration:00:26:08

Episode 26: FDA shows its teeth, biotech fish oil might be pointless, & treating McCain's cancer

8/30/2018
More
Is the FDA as lenient as everyone thinks? Can fish oil be a multibillion-dollar drug? And why aren't there better treatments for brain cancer?

Duration:00:17:56

Episode 25: A genome-editing first, Trump on Wall Street, and biotech red flags

8/23/2018
More
Can genome-editing work in actual people? Are CEOs oversharing? And how do you sniff out a bad bet before it happens?

Duration:00:21:47

Episode 24: A lesson in startup jargon, pharma's bare Alzheimer's cupboard, and the cost of CAR-T

8/16/2018
More
How much is a shot at curing cancer worth? Where are all the drugs for late-stage Alzheimer's disease? And what on Earth is an "oversubscribed Series A round"?

Duration:00:23:52

Episode 23: Congressional insider trading, PETA and fake meat, & doctors vs. fund managers

8/9/2018
More
Can insider trading charges derail political campaigns? Should you trust a fund manager over a doctor? And how many rats would you trade for a cow?

Duration:00:21:09

Episode 22: Biotech's battle for talent, Sanofi's second act, and climbing Mt. Everest

8/2/2018
More
What juicy perks do biotech startups offer to lure increasingly hard-to-find talent? How does Sanofi plan to make up for lost time in the lucrative field of oncology? And veteran biotech journalist Luke Timmerman talks about what it's like to climb Mt. Everest.

Duration:00:23:02

Episode 21 - A debatable Alzheimer's breakthrough, Gilead's golden age, and "robust" data

7/26/2018
More
What qualifies as "robust" when it comes to data? Is digital health a bubble? And can Gilead Sciences survive without men named John?

Duration:00:24:58

Episode 20 - CRISPR freakouts, drug prices meet elections, and a busy earnings season

7/19/2018
More
Can drug prices swing an election? Is every quarter a “great quarter“? And why is everyone freaking out about CRISPR? Listen, and all will be explained.

Duration:00:25:30

Episode 19: Trump's telephonic prowess, Biogen's mysterious future, & the rise of 'hypelines'

7/12/2018
More
Can phone calls bring down drug prices? Do mom-and-pop investors have a prayer against hedge funds? And how do you know whether an Alzheimer's drug actually works?

Duration:00:24:45

Episode 18: Biotech's six-month review, how to become a day trader and soul-searching analysts

7/5/2018
More
Adam and Damian recap the past six months in biotech. Investor and philanthropist, Sheff Station, stops by and gives tips on how to become a day trader, and analysts questioning their very existence.

Duration:00:19:48

Episode 17: A friendly FDA, biosimilar awkwardness and how to sell drugs in China

6/28/2018
More
How did the FDA become so friendly to the drug industry? The thorny issue of using 23andMe to unite families separated at the border, and Rebecca explains how drugs are priced in China.

Duration:00:23:11

Episode 16: Sarepta's big week, Theranos' legal woes and parsing AI hype

6/21/2018
More
Is Sarepta Therapeutics worth $10 billion? Will Theranos' Elizabeth Holmes go behind bars? And how does AI fit into biotech?

Duration:00:25:45

Episode 15: Problematic parties, Nitpicking NASH, and an opioid documentary from STAT

6/14/2018
More
The problem with the topless dancers at PABNAB. Are investors overestimating the market for fatty liver drugs? And how many lives do biotech entrepreneurs get?

Duration:00:23:45

Episode 14: Twitter vitriol, biotech jargon, and the plight of the CEO

6/7/2018
More
Why is Twitter so mean to Axovant? Adam teaches a crash course on biostatistics. And will sci-fi gene and cell therapies ever go mainstream.

Duration:00:26:56

Episode 13: Spending millions on fatty liver disease. Overhyped cancer drugs. Who goes to BIO?

5/31/2018
More
Is the drug industry spending millions on a made-up disease? Have the latest cancer drugs been overhyped? And why does anyone go to BIO?

Duration:00:22:31

Episode 12: Ebola should worry you, again; 23andMe's World Cup whoops; Don't drink sunscreen

5/24/2018
More
How worried should you be about Ebola? Can the government lower drug prices without hurting the drug industry? And is socceromics a thing? Listen this week to find out.

Duration:00:27:48

Episode 11: Inside the Theranos collapse, Valeant's latest legal lumps, and a few biotech hot takes

5/17/2018
More
What do you call a unicorn without a horn? Is your colleague wearing a wire? And is Jentadueto a drug name or a complicated espresso drink?

Duration:00:22:44

Episode #10: Cohen, Trump, Novartis, oh my; Spark + Amish; Genetic testing at your doc's office?

5/10/2018
More
On today's show, we dig into the no good, very bad day Novartis had when the world got wind of its ties to President Trump's personal attorney, a discussion of how the world's biggest cancer conference used to be the Wild West for investors, and an exploration of one health system's plan to bring genomics to the masses. Also STAT's Eric Boodman joins us to talk about how a pricey new gene therapy has created a fascinating situation in Amish country.

Duration:00:22:28